Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO1234)

• Drug Name: TNX-102 Drug Info
• Synonyms: Cyclobenzaprine very low dose

Indication

Disease Entry	ICD 11	Status	REF
Fibromyalgia	MG30.01	Phase 3	[1]
Post-traumatic stress disorder	6B40	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 22576
  ChEBI ID: CHEBI:3997
  CAS Number: CAS 6202-23-9
  TTD Drug ID: DMO1234

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[4]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[5]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[6]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[7]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[8]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[9]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[10]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[11]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[12]
IDAZOXAN HYDROCHLORIDE	DMSP0X8	Neurological disorder	6B60	Phase 3	[13]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[14]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[15]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[16]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[17]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[18]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[19]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[20]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[21]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[22]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Antagonist	[3]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Antagonist	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017946)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [4] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [5] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [7] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [8] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [9] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [10] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [11] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [12] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [13] Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4.
• [14] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [15] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [16] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [17] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [18] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [19] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [21] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [22] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [23] Clinical pipeline report, company report or official report of Lundbeck.